{
    "2019-10-23": [
        [
            {
                "time": "2018-10-15",
                "original_text": "UPDATE 1-J&J slashes third-quarter profit by $3 bln over proposed opioid deal",
                "features": {
                    "keywords": [
                        "J&J",
                        "slashes",
                        "third-quarter",
                        "profit",
                        "opioid",
                        "deal"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-16",
                "original_text": "Johnson & Johnson restates earnings over opioid settlement",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "restates",
                        "earnings",
                        "opioid",
                        "settlement"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-17",
                "original_text": "J&J slashes third-quarter profit by $3 billion over proposed opioid deal",
                "features": {
                    "keywords": [
                        "J&J",
                        "slashes",
                        "third-quarter",
                        "profit",
                        "opioid",
                        "deal"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-18",
                "original_text": "J&J says proposed opioid settlement to lower reported Q3 profit by $3 bln",
                "features": {
                    "keywords": [
                        "J&J",
                        "opioid",
                        "settlement",
                        "Q3",
                        "profit"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-19",
                "original_text": "2 Sells and 1 Buy in Opioid Stocks",
                "features": {
                    "keywords": [
                        "Sells",
                        "Buy",
                        "Opioid",
                        "Stocks"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-10-20",
                "original_text": "Johnson & Johnson Confirms $4 billion 'Agreement in Principle' Opioid Settlement",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "Confirms",
                        "$4",
                        "billion",
                        "Opioid",
                        "Settlement"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-21",
                "original_text": "Is the Worst Over for Johnson & Johnson?",
                "features": {
                    "keywords": [
                        "Worst",
                        "Over",
                        "Johnson",
                        "&",
                        "Johnson"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-22",
                "original_text": "Does Johnson & Johnson (NYSE:JNJ) Have A Healthy Balance Sheet?",
                "features": {
                    "keywords": [
                        "Johnson",
                        "&",
                        "Johnson",
                        "Healthy",
                        "Balance",
                        "Sheet"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-23",
                "original_text": "J&J Recalls Baby Powder After Asbestos Find — Is JNJ Stock A Safe Buy?",
                "features": {
                    "keywords": [
                        "J&J",
                        "Recalls",
                        "Baby",
                        "Powder",
                        "Asbestos",
                        "Find",
                        "Safe",
                        "Buy"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-10-24",
                "original_text": "Health-Care Stocks Gain as Elizabeth Warren’s Victory Looks Less Assured",
                "features": {
                    "keywords": [
                        "Health-Care",
                        "Stocks",
                        "Gain",
                        "Elizabeth",
                        "Warren",
                        "Victory",
                        "Less",
                        "Assured"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}